Article Text

PDF
THU0484 Impact of TNF Antagonists on the Joint Manifestations of Sarcoidosis
  1. C. Banse1,
  2. A. Bisson-Vaivre1,
  3. M. Kozyreff-Meurice1,
  4. S. Dominique1,
  5. O. Vittecoq1,
  6. V. Goeb2
  1. 1Rheumatology, Rouen
  2. 2Rheumatology, Amiens, France

Abstract

Objectives Use of anti-TNF agents to treat joint manifestations of sarcoidosis has not been described. We evaluated the efficacy and safety of 3 such biologics in patients with these symptoms refractory to conventional therapy (NSAIDs, corticosteroids and/or DMARDs).

Methods This retrospective study, covering January 2001 to September 2011, examined the following clinical–biological parameters collected before anti-TNF treatment (age, sex, duration of disease evolution, drugs taken), and at introduction and under anti-TNF therapy (number of painful and swollen joints, visual analogue-scale score of global disease activity, Disease Activity Score-28 with ESR or CRP, TNF-antagonist duration). At 3, 6 and 12 months, anti-TNF impact on joints and the therapeutic response according to EULAR criteria used for rheumatoid arthritis were assessed.

Results Ten patients data were evaluated; some of them had received several anti-TNF agents (median (range) duration on each biotherapy was 10 (4–30) months), which enabled analysis of 19 prescriptions. The total duration of anti-TNF exposure was 17.6 patient-years, that was started a median of 3 (0.33–17) years after sarcoidosis diagnosis. The median numbers of painful and swollen joints were, respectively, 1 (0–28) and 0 (0–9). Despite rapid efficacy, after 1 year of treatment, clinical (especially joint) and biological parameters were comparable to pretreatment and only the corticosteroid dose was significantly lower (P = 0.03). One case of mild skin toxicity was noted.

Conclusions TNF antagonists allowed significant steroid-sparing and were well-tolerated but do not seem to be effective against sarcoidosis joint involvement.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.